methotrexate has been researched along with Hypercoagulability in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cabré, E; Domènech, E; Leal-Valdivieso, C; Mañosa, M; Naves, JE; Zabana, Y | 1 |
| Altomare, M; Crescenzio, N; De Mattia, D; Del Vecchio, GC; Falanga, A; Giordano, P; Marchetti, M; Molinari, AC; Perutelli, P; Russo, G; Santoro, N; Saracco, P | 1 |
| Ely, SF | 1 |
| Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P | 1 |
4 other study(ies) available for methotrexate and Hypercoagulability
| Article | Year |
|---|---|
[Portal hypertension in patients with inflammatory bowel disease].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Ascites; Crohn Disease; Female; Humans; Hypertension, Portal; Immunosuppressive Agents; Inflammatory Bowel Diseases; Intestinal Pseudo-Obstruction; Liver Cirrhosis; Mesalamine; Mesenteric Veins; Methotrexate; Splenomegaly; Thioguanine; Thrombophilia; Varicose Veins | 2010 |
Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Antithrombins; Asparaginase; Case-Control Studies; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Fibrin Fibrinogen Degradation Products; Humans; Infant; Longitudinal Studies; Male; Mercaptopurine; Methotrexate; P-Selectin; Plasminogen Activator Inhibitor 1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Risk Factors; Thrombin; Thrombophilia; Venous Thromboembolism; Vincristine; von Willebrand Factor | 2010 |
Potential risk of a common hereditary thrombophilia and adjuvant chemotherapy for low-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Fatal Outcome; Female; Fluorouracil; Homocysteine; Humans; Methotrexate; Middle Aged; Mutation; Risk; Thrombophilia | 2005 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine | 1997 |